Key Highlights

  • The names are ranked by size of pre-market fall on Wednesday, October 28, 2026, so Nuwellis (NASDAQ:NUWE) leads. It is the only one of the four that fell after a favourable study release dated Tuesday, October 27, 2026.
  • Lakewood-Amedex (NASDAQ:LABT) is a repeat faller, quoted near USD 0.26 in two consecutive pre-market sessions, with cash of about USD 4.6 million set against a quarterly net loss of about USD 3.8 million.
  • Steakholder Foods (NASDAQ:STKH) carries the most explicit funding warning in the group, since its half-year filing questions the ability to continue as a going concern, while warrants and a depositary ratio change add dilution overhang.
  • Baird Medical (NASDAQ:BDMD) is the only name with a reported first-half profit, yet it slipped without a dated announcement, and the Federal Reserve decision is due later on Wednesday, October 28, 2026.

Nuwellis (NASDAQ:NUWE): a fall that runs against a favourable study

The Aquadex system, which removes fluid from patients with fluid overload, is sold by Nuwellis (NASDAQ:NUWE), a medical device company. Pre-market on Wednesday, October 28, 2026 it was at USD 4.75, down 12.20%. The closest catalyst is a release issued at 8:00 a.m. ET on Tuesday, October 27, 2026, announcing that Pediatric Nephrology had accepted a multicentre study of Aquadex in children. Because the findings are favourable, the move runs against the news and looks like profit-taking or thin trading, an inference. The ULTRA-Peds Registry covered 91 patients at seven hospitals, with 87% surviving the treatment course, and the company plans to seek a label expansion from 20 kg and above down to 5 kg and above.

Second quarter revenue of USD 2.0 million, up 14%, a gross margin of 76% against 56% a year earlier, and a net loss of USD 4.8 million were reported in the company's release of Thursday, August 13, 2026. Cash was USD 3.9 million at June 30, 2026 and about USD 8.8 million at August 31, 2026, which should fund operations into the third quarter of 2027. Upside: a label from 5 kg would widen the addressable paediatric population. Downside: quarterly revenue is small, no formal financial guidance exists and approval is not assured. Dilution from further financing and thin liquidity are the named risks.

Lakewood-Amedex (NASDAQ:LABT): a second decline at a funding-constrained developer

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a clinical-stage company developing antimicrobial drugs from its Bisphosphocin platform. It traded at USD 0.2610 in the pre-market snapshot of Wednesday, October 28, 2026, a fall of 8.81%. That implies a prior close near USD 0.286, from simple arithmetic on the two published figures. The pre-market price on Tuesday, October 27, 2026 was USD 0.2632. No company-specific announcement dated on or just before Wednesday, October 28, 2026 came with the move, and the decline seems consistent with thin liquidity and a funding need at a micro cap company without revenue.

The quarterly report filed on Friday, August 14, 2026 showed no revenue for the three months ended June 30, 2026. The lead candidate, Nu-3, a topical gel for infected diabetic foot ulcers, is being prepared for a Phase 2a trial, with no start date stated. Upside rests on the preclinical poster listed for Thursday, October 22, 2026 and on a trial design that could support a Phase 2b study. Downside rests on a near-term financing need, dilution through new equity or conversion of the Series C preferred stock and Nasdaq minimum bid price compliance, with the shares below USD 1.00.

Steakholder Foods (NASDAQ:STKH): thin trading and dilution overhang

Food technology company Steakholder Foods (NASDAQ:STKH) sells its Perfecta plant-based meat range in United States retail through the distributor KeHE, while its subsidiary Twine Solutions sells textile dyeing systems. Pre-market on Wednesday, October 28, 2026 it traded at USD 0.3800, down 7.77%, after USD 0.3749 in the Tuesday, October 27, 2026 snapshot. No company-specific announcement dated on or just before the session came with the move, and the latest release, of Thursday, September 3, 2026, covers the Perfecta retail launch. Thin liquidity and the overhang from recent financings seem to explain the decline, an inference.

The filing reported a total comprehensive loss of USD 3.3 million for the six months to Tuesday, June 30, 2026, against USD 3.8 million a year earlier, and cash of USD 1.1 million. It states that cash is not sufficient to fund operations for at least 12 months. Roughly USD 4.3 million net was raised in July and August 2026 under a private placement of up to USD 10.5 million at USD 2.00 per American depositary share, so the quote sits about 81% below that price on simple arithmetic. Series E and F warrants for up to 3,500,000 shares become exercisable only after shareholder approval and registration.

Baird Medical (NASDAQ:BDMD): profit and approvals without a dated trigger

Microwave ablation systems are sold by Baird Medical Investment Holdings Limited (NASDAQ:BDMD). In the pre-market snapshot of Wednesday, October 28, 2026 it was at USD 0.2601, a fall of 7.73%. No company-specific announcement dated on or just before that day came with the move. The latest items are the company's statement of Monday, October 19, 2026 on Class C registrations in Vietnam and preliminary approval in Egypt for its BD-GT system, and its update of Monday, October 5, 2026 on global expansion in the third quarter. Thin liquidity and profit-taking in a low-priced security seem consistent with the decline, an inference.

Preliminary unaudited results for the six months to June 30, 2026 were reported in the release of Thursday, September 3, 2026: revenue of about USD 9.9 million, up 24.6%, a gross margin of 87.0% and net income of USD 13,499, compared with a net loss of USD 11.4 million a year earlier. Bulls rest their case on that swing and on registrations that support diversification away from mainland China, where 2025 revenue fell 39.2% after a policy-related slowdown. Bears note that profit is marginal, the figures are unaudited and a share under USD 1.00 raises possible minimum bid price questions. No cash balance was stated.

Where Things Stand

Whether a gain holds depends more on balance sheet capacity than on the direction of the last session. Nuwellis (NASDAQ:NUWE) has a favourable study and a stated runway, so its fall rests mainly on trading mechanics. Baird Medical (NASDAQ:BDMD) reports a profit, but on preliminary figures. Lakewood-Amedex (NASDAQ:LABT) and Steakholder Foods (NASDAQ:STKH), the two repeat fallers, depend on financing that has not yet been announced for either.

The next catalysts are the Federal Reserve decision due later on Wednesday, October 28, 2026, the Vivian advisory board meeting of Nuwellis on Wednesday, November 18, 2026 and Thursday, November 19, 2026, a Nu-3 trial start or financing for Lakewood-Amedex, any shareholder meeting notice for Steakholder Foods and audited interim figures for Baird Medical. Pre-market prices are snapshots that can change, and this is not investment advice.